Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study

Trial Profile

Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug (DT) (20mg/m2 and 30mg/m2) to Those of Best Supportive Care (BSC) in Patients Suffering From Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Doxorubicin (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ReLive
  • Sponsors BioAlliance Pharma; Onxeo SA
  • Most Recent Events

    • 23 May 2017 According to an Onxeo media release, the company has received the 10th recommendation from the Data Safety Monitoring Board (DSMB), to continue this study without modification
    • 25 Jan 2017 Status changed from recruiting to active, no longer recruiting, according to Onxeo SA media release.
    • 13 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top